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Proteomic analysis of synovial fluid 
from rheumatic arthritis and spondyloarthritis 
patients
Svend Birkelund1,5* , Tue Bjerg Bennike1 , Kenneth Kastaniegaard1,2 , Mads Lausen1 ,  
Thomas Bouet Guldbæk Poulsen1 , Tue Wenzel Kragstrup3,4 , Bent Winding Deleuran3,4 , 
Gunna Christiansen1  and Allan Stensballe1 
Abstract 
Background: The aetiologies and pathogeneses of the joint diseases rheumatoid arthritis (RA) and spondyloarthri-
tis (SpA) are still not fully elucidated. To increase our understanding of the molecular pathogenesis, we analysed the 
protein composition of synovial fluid (SF) from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients.
Methods: Fifty-six synovial fluid samples (RA, n = 32; SpA, n = 24) were digested with trypsin, and the resulting 
peptides were separated by liquid chromatography and analysed by tandem mass spectrometry. Additionally, the 
concentration of cell-free DNA (cfDNA) in the synovial fluid was measured, and plasma C-reactive protein (CRP) was 
determined.
Results: Three hundred thirty five proteins were identified within the SF. The more abundant proteins seen in RA 
SF were inflammatory proteins, including proteins originating from neutrophil granulocytes, while SpA SF had less 
inflammatory proteins and a higher concentration of haptoglobin. The concentration of cell-free DNA in the SF 
increased together with proteins that may have originated from neutrophils. Plasma CRP levels in both RA and SpA, 
correlated to other acute phase reactants.
Conclusions: The proteomic results underline that neutrophils are central in the RA pathology but not in SpA, and 
even though inhibitors of neutrophils (migration, proteinase inhibitors) were present in the SF it was not sufficient to 
interrupt the disease process.
Keywords: Proteomics, Synovial fluid, Rheumatoid arthritis, Spondyloarthritis, Cell-free DNA, Neutrophil extracellular 
traps
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Background
The rheumatic diseases constitute a group of diseases 
that affects joints, ligaments, tendons, bones and can 
also show systemic manifestations. Rheumatoid arthri-
tis (RA) and spondyloarthritis (SpA) are common 
inflammatory systemic joint diseases, with a prevalence 
of 0.5–1% and 0.1–0.3% respectively [1, 2]. RA is char-
acterized by autoantibodies, including antibodies to 
citrullinated proteins (adaptive immune system) and 
neutrophil infiltration (innate immune system) of the 
synovial fluid (SF), whereas SpA is an autoinflammatory 
disorder of the innate immune system [3]. RA is twice 
as common in women, while SpA is twice as common 
in males [1, 4]. RA typically affects the small joints of 
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and bone destruction can occur. In SpA, arthritis often 
affects the small joints of the spine, sacroiliac joints, 
and large joints of the extremities. As both diseases 
progress, cartilage and bone destruction often occur. 
Extra articular manifestations can include enthesitis, 
psoriasis, uveitis, and inflammatory bowel disease.
Diagnosis of RA and SpA is based on the clinical 
manifestations, genetic- and biochemical markers, 
accompanied by imaging techniques (radiographs and 
magnetic resonance imaging)[5, 6]. The two main sero-
logical tests for the RA diagnosis are rheumatoid fac-
tor (RF) [7], and anti-citrullinated protein antibodies 
(ACPA) [8]. Citrullination is a deamination of the side 
chain of the amino acid arginine catalysed by citrulli-
nating enzymes, peptidyl arginine deiminases (PAD), in 
particular PAD4 and PAD2, of which single nucleotide 
polymorphisms in PAD4 are associated with RA sus-
ceptibility [9]. In RA both RF and ACPA are positively 
associated with the development of a more severe dis-
ease progression [10].
In SpA, MHC class I type HLA-B27 is present in up 
to 90% of the patients [11] and with less than 5% of the 
patients being RF or ACPA positive [12]. The two dis-
eases can thereby be differentiated, but in rare cases the 
two diseases can co-exist [13]. In both diseases C-reac-
tive protein (CRP) can be increased during active disease. 
Additionally, in spite the known differences, understand-
ing of the RA and SpA aetiologies remains incomplete.
The protein composition (Proteome) of SF has previ-
ously been investigated. By use of 2D-gel electrophore-
sis Noh et al. [14] analysed the proteome of SF from RA 
patients early and late in the disease development and 
compared it with serum from healthy donors. They found 
several low molecular weight proteins in the SF com-
pared with serum. In addition, they showed that tumour 
necrosis-alpha-induced Adipose-Related Protein and 
Zinc Finger Protein, ZNF658, could be detected as pos-
sible markers for RA in serum. Using LC-MS/MS based 
proteomics Mateos et  al. [15] pooled SF from 20 RA 
patients and compared the results to a pool of 20 SF from 
osteoarthrosis (OA) patients. They found proteins related 
to inflammation to be dominant in the RA group, and 
proteins involved in the formation and remodelling of the 
extracellular matrix in the OA group. Similar results were 
obtained by Balakrishnan et  al. [16] who pooled 5 RA 
and 5 OA samples, respectively, and also found increased 
amounts of inflammatory markers of the S100 protein 
family and matrix metalloproteinases (MMP) in the RA 
group.
Using quantitative proteomics, Mahendran et  al. [17] 
analysed individual SF samples from 10 RA, 10 psoriatic 
arthritis patients (PsA) and 10 controls. PsA is a sub-
group of SpA and, compared to the controls, MMP3 was 
highly increased in both disease groups. Overall, the SF 
proteomics of PsA and SpA were highly similar.
To determine the molecular differences in SF from RA 
and SpA patients, we characterized the proteome of 56 
individual SF samples from RA (n=32) and SpA (n=24) 
patients. This allowed us to avoid pooling samples and 
thereby reveal minor differences between the disease 
groups. To compare proteomic results with biochemical 
parameters, C-reactive protein (CRP) in plasma as acute 
phase marker, and cell-free DNA (cfDNA) as SF pseudo-
marker for neutrophil extracellular traps (NETs) were 
determined [18].
Methods
Human subjects and biobank samples
The clinical samples were collected under the pro-
ject “INflamation in ARThritis (INART), approved 
by The Central Denmark Region Committees on 
Health  Research Ethics (1-10-72-291-12). All patients 
were >18 years of age, fulfilling the ACR/EULAR cri-
teria for RA and ASAS criteria for SpA, respectively [6, 
19]. The diagnosis was supported by determination of RF 
(38% positive) and ACPA (42% positive) for RA patients, 
and by determination of HLA-B27 for SpA patients (84% 
positive) determined by Department of Biochemistry at 
Aarhus University Hospital, Denmark.
Sodium dodecyl sulphate‑polyacrylamide gel 
electrophoresis of SF
SF was cleared for cellular debris by centrifugation at 
600×g for 15 min at 20 °C, before storage at -80 °C. After 
thawing, the samples were centrifuged at 20,000×g for 
10 min at 4 °C. The protein concentration was measured 
with the Bicinchonic Acid (BCA) Protein Assay (Thermo 
Fisher Scientific, Waltham, MA) according the manu-
factures instruction. Five µg protein in SDS-samples 
buffer (Expedeon, San Diego, CA) were separated by 12% 
SDS-polyacrylamide gel electrophoresis (Expedeon). 
As molecular weight standard, 2.5 µl  Mark12® (Thermo 
Fisher Scientific) was used. The proteins were stained 
with Krypton™ Fluorescent Protein Stain (Thermo Fisher 
Scientific) according the manufactures instruction and 
scanned on an Amersham Typhoon Biomolecular Imager 
(GE Healthcare, Chicago, IL).
Sample preparation for proteomics
For sample preparation “filter-aided sample prepara-
tion” (FASP) was used [20, 21]. Briefly, 100 µg SF-protein 
was dissolved in 5% (w/v) sodium deoxycholate (SDC) 
in 50 mM triethylammonium bicarbonate (TEAB). 
The samples were heated to 90 °C for 5  min. Molecu-
lar weight cut-off Spinfilters 10 kDa (YM10; Millipore, 
Sigma-Aldrich, St. Louis, MO, USA) were used for buffer 
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exchange between the different steps. The samples were 
reduced with 12 mM Tris(2-carboxyethyl) phosphine 
hydrochloride (TCEP), alkylated with 40 mM iodoaceta-
mide (IAA) and digested with 0.4 μg sequencing grade 
modified trypsin (Promega, Fitchburg, Wisconsin, USA) 
resuspended in 0.5% SDC, 50 mM TEAB. After digestion, 
the peptides were collected, and acidified with 0.1% trif-
luoroacetic acid (TFA). The peptide product was purified 
using ethyl acetate extraction and the final product was 
dried down in a vacuum centrifuge and stored at − 80 
°C. Prior to analysis, the samples were resuspended in 2% 
acetonitrile (ACN) and 0.1% TFA.
Mass spectrometry‑based proteomics analysis
The mass spectrometry-based analysis was performed 
according to Bennike et al. [20] in a randomized patient 
order. The protein solution was analysed on an auto-
mated LC-electrospray ionization (ESI) MS/MS system 
using an Ultimate 3000 UPLC system with a nanopump 
module. The system was coupled online to a Thermo-
Electron Q Exactive Plus mass spectrometer (Thermo 
Scientific, Waltham, USA) with an emitter for nanospray 
ionization. Triplicate runs of each sample (5% of digested 
material) were loaded onto the C18 reversed phase col-
umn (Dionex; Acclaim PepMap100 C18, 5 μm precolumn 
and 50 cm Acclaim Pepmap RSLC, 75 μm ID main col-
umn, Thermo Scientific) and eluted with a linear gradi-
ent of 96% solvent A (1% formic acid) and 4% solvent B 
(acetonitrile)[20] which was increased to 35% solvent B 
on a 90 min ramp gradient. The MS was operated in data 
dependent acquisition (DDA) mode, selecting the 12 pre-
cursor-ions with the highest intensity for higher energy 
collisional dissociation (HCD) fragmentation. The raw- 
and processed data have been made available via Pro-
teomeXchange with identifier PXD010723 [22].
Proteomics data analysis
A label-free analysis of the proteomics data was per-
formed in MaxQuant v1.6.0.1. The fragment scans 
were searched against a Uniprot database containing all 
reviewed Homo sapiens proteins.
(Uniprot reference proteome UPID5640; downloaded 
08.2017). The following abundant peptide modifications 
were included in the analysis: carbamidomethylated 
cysteine residues (fixed), acetylation of N peptides from 
the N-terminal of proteins (variable), and oxidation of 
methionine (variable). The build-in MaxQuant target-
decoy search strategy was applied and used to adjust 
the false discovery rate (FDR) of identified peptides and 
proteins to max 1%. The MaxQuant MaxLFQ feature, 
which estimates peptide and protein abundances based 
on normalized summed peptide precursor intensities, 
was applied. The resulting label free protein abundance 
(LFQ) data was processed in Perseus v1.6.0.2 [23]. All 
protein abundances were log2-transformed. Only for the 
unsupervised principle component analysis (PCA), did 
we replace (imputed) missing values with values drawn 
from a normal distribution to circumvent the prob-
lem that PCA cannot handle missing values [24, 25]. 
This was done by using standard parameters in Perseus 
for label-free proteomics data, to simulate signals from 
low-abundant proteins (width = 0.3, downshift = 1.8). 
Technical replicates were combined by the median, and 
differentially expressed proteins were identified by t-tests, 
corrected for multiple hypothesis testing using permuta-
tion-based false-positive control with standard param-
eters in Perseus (s0 = 0.1, FDR < 0.05). Protein function 
was analysed using Gene Ontology (GO) nomencla-
ture from UniProt protein knowledgebase (UniProtKB) 
(http://www.unipr ot.org) annotation and the software 
tool “Software tool for researching annotations of pro-
teins” (STRAP) [26]. Unsupervised hierarchical cluster-
ing with Euclidean distance calculations was performed 
on z-score normalized data using standard parameters 
in Perseus (300 clusters, 10 iterations). Pearson’s correla-
tion analyses of the LFQ values were performed as previ-
ously described [27]. Finally, for exploratory analyses we 
performed linear mixed effect models and random forest 
modelling using R.
C‑reactive protein
CRP was measured at the Department of Biochemistry at 
Aarhus University Hospital as part of routine care using a 
Cobas 6000 (Chemistry XPT).
Cell‑free DNA measurement
SF was thawed and centrifuged at 15,000×g for 15 min, 
diluted 1:25 in 10 mM Tris, pH 8.0 with 1 mM EDTA 
(TE-buffer). The Quant-iT™ PicoGreen™ dsDNA Assay 
Kit (ThermoFisher Scientific) was used according to the 
manufacture’s instruction using 96 well Microplates, PP, 
F-Bottom black chimney well design (Sigma Aldrich). 
Fourfold dilution series of DNA were included on all 
plates (1 µg/ml, 250 ng/ml, 62 ng/ml, 15.6 ng/ml, 3.9 ng/
ml, 970 pg/ml, 243 pg/ml, 0 pg/ml). Samples and stand-
ards were prepared and measured in duplicates. Plates 
were measured on an Enspire Multimode Plate Reader 
(Perkin Elmer, Waltham, MA) with excitation 480 nm 
and emission 520 nm.
Results
Patient material
SF was obtained from patients visiting the outpatient 
clinic at Aarhus University Hospital at the time when 
therapeutic arthrocentesis was performed. Of the 32 
RA patients, five were in treatment with TNF inhibitors 
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 (Adalimumab®,  Certolizumab® or  Etanercept®), four 
with the IL-6 receptor antagonist  Tocilizumab® and three 
with T-cell activation inhibitor  Abatacept®. Nineteen of 
the RA patients were in methotrexate treatment. Of the 
24 SpA patients 6 were in treatment with TNF inhibitors 
and one with  Abatacept®. In the RA group 38% was posi-
tive for RF and 42% positive for ACPA. In the group of 
SpA patients 84% was of the HLA-B27 tissue type.
SDS‑PAGE analysis of SF
The protein concentration in the 56 SF-samples varied 
from 15.7 to 55.4 mg/ml with a mean of 38.1 mg/ml, 
which is slightly higher than the ~ 25 mg/ml reported in 
SF from healthy persons. The higher protein-concentra-
tion is likely caused by the inflammation [28]. To ana-
lyse for major differences in the protein composition, all 
SF-samples were visualized by 12% SDS-PAGE (Fig.  1a, 
patient number 12–22). Human albumin bands with 
a size of 66.5 kDa were seen in all samples with a simi-
lar intensity, showing that the adjusted protein load was 
identical for all samples. Variation was only seen in band 
patterns below 20 kDa. Comparing the samples, there 
was no observable correlation between the low molecu-
lar weight band patterns and the diagnosis. SF is a filtrate 
of plasma plus proteins produced locally in the joint. 
Therefore, we compared a SF sample from a SpA patient 
to plasma from a healthy participant using SDS-PAGE 
(Fig.  1b), and only minor differences in low molecular 
weight bands were seen between normal plasma and SF 
from SpA patient 19. This indicates that the majority of 
proteins in an inflamed joint is plasma-derived proteins.
Quantitative proteomics analysis of SF proteins in RA 
and SpA
Because of the high similarity between the overall protein 
composition of RA and SpA samples, a label-free prot-
eomics analysis was performed to get a deeper proteome 
coverage and obtain relative quantitative information to 
reveal the differences in SF of the 56 samples (RA n = 32, 
SpA n =24). Each SF sample was digested in solution 
with trypsin, separated by nanoUPLC and peptides were 
sequenced using tandem MS by HCD fragmentation. All 
a b
Fig. 1 12% SDS-PAGE of SF and plasma stained with Krypton™ Fluorescent Protein Stain. a Lane 1: Molecular weight standard. Lanes 2–12: SF from 
patient 12–22. The diagnosis is marked over the patient numbers, SpA and RA. b Comparison of normal plasma with
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samples were analysed in triplicates, resulting in 168 MS-
runs. Cumulated, we identified 335 proteins (false dis-
covery rate (FDR) < 1%). Following stringent filtering to 
ensure high-quality quantitative data, 266 proteins were 
quantifiable cumulated in the SF samples (Additional 
file 1: Table S1).
Overall SF proteome segregation by gene ontology 
characterization
The quantifiable proteins were classified according 
to their functional Gene ontology (GO) information 
obtained from UniProtKB and GO annotation and visu-
alized with the STRAP software according to “biologi-
cal process” and “cellular component” (Fig. 2). As shown 
in Fig.  2a (biological processes), characterization of the 
biological process (Fig. 2a) identified 85 proteins associ-
ated with the immune system, and in addition the groups 
“regulation” and “cellular process” were dominant. The 
GO cellular component (Fig.  2b) showed that 252 pro-
teins were classified as “extracellular” in agreement with 
SF being an extracellular fluid. In addition, many pro-
teins have the annotation “Other intracellular organelles”. 
This GO nomenclature covers the secretory pathway 
group. Furthermore, few proteins are seen in the groups: 
“nucleus”, “cytoplasm” and “cytoskeleton”, supporting 
a high degree of cellular infiltration in SF from these 
patients.
Comparison of RA and SpA proteomes by Principal 
component analysis (PCA)
The overall similarities between the 168 LC–MS runs 
were investigated by an unsupervised PCA plot on the 
complete data set before merging the technical tripli-
cates. The scores plot revealed that the technical repeats 
mostly cluster together (Fig. 2c, encircled). This demon-
strates a smaller technical variance than interpersonal 
difference between the samples, as expected for a sensi-
tive and robust analysis method. The first principal com-
ponent (the largest possible variation 21%, X-axis) does 
not discriminate between RA and SpA patients (Fig 2c), 
whereas the second component (highest variance to first 
component 11%, Y-axis) is discriminative for some of the 
RA patients (Fig 2c).
Proteins that contribute the most to the variation 
in component one and two were analysed by a fac-
tor loading plot (Fig.  2d). Principle component 1 was 
largely separated based on haptoglobin (HP), Fibrino-
gen beta chain (FGB) and several immunoglobulin 
proteins encoded from variable (V) gene segments 
of both heavy chain and light chain. Principle com-
ponent 2 became separated on basis of inflamma-
tory proteins, including Myeloperoxidase, S100-A12 
protein, Lysozyme C, Cathepsin G and Neutrophil 
gelatinase-associated lipocalin. (Fig. 2d). This indicates 
that the PC2 separation is based on the inflammatory 
joint status of the patients. Accordingly, the four RA 
patients with the highest PC2-value (pt. 22, 25, 34, and 
64) had significantly increased SF IgM (mean increase 
6.34, p-value 0.04). In these patients CRP was also 
increased, although not significantly.
Analysis of SF protein differences between RA and SpA
Comparing all identified proteins of RA to all of SpA 
using t-tests, none of the proteins passed multiple 
hypothesis correction (q-value < 0.05). However, applying 
a less strict cut-off without multiple hypothesis correc-
tion (p-value < 0.05, log2 (fold change) > 0.5 or < − 0.5), 
25 more abundant proteins in RA compared to SpA were 
identified, in addition to 4 less abundant proteins (Fig. 2e, 
Table 1). The majority of the more abundant RA-proteins 
are present in neutrophil granulocytes and monocytes 
(Table 1 marked a) or proteins involved in the glycolysis 
(Table  1 marked b). This is in agreement with the pre-
liminary conclusions from the PCA, and indicates the 
presence of infiltrating neutrophils in the SF from RA 
patients, in agreement with previous reports [3]. In addi-
tion, the data demonstrates the significantly lower/lack of 
infiltrating neutrophils in SpA, highlighting a central dif-
ference in the pathogenesis of RA and SpA.
Correlation of protein changes to concentration of cell‑free 
DNA in SF
Cell-free DNA (cfDNA) in plasma is an inflammatory 
marker for RA and has been proposed as a predictive 
marker for biological disease-modifying anti-rheumatic 
drugs (DMARD) treatment [29, 30]. cfDNA in the SF 
was measured by a fluorometric method. The SF cfDNA 
concentration was found to vary between 0.5 to 42.2 µg/
ml. These values are an order of tree magnitude higher 
than can be observed in plasma from RA patients [29, 
30], and it reflects that cfDNA originates from cells pre-
sent in SF. SF cfDNA could be measured in both patient 
groups, but no statistically significant difference between 
the intra articular cfDNA concentrations was observed 
between the RA and SpA patients  (RAmean = 7.3 µg/ml, 
 SpAmean = 5.1 µg/ml, t-test p-value = 0.30) (Fig.  2f ). The 
SF samples were centrifuged to remove cells before freez-
ing and to avoid the release of cellular DNA. However, it 
cannot be excluded that cell lysis occurred after collec-
tion and prior to centrifugation. With this reservation 
in mind, the SF levels of cfDNA was correlated to the SF 
protein abundance levels to identify functional proteins, 
which could elucidate the biological interpretation of the 
cfDNA measurements. Sixty-eight proteins correlated 
significantly (p-value < 0.05) with the amount of cfDNA 
in the SF (Table 2).
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Correlation of proteins found changed/increased 
by proteomic in SF to regulatory pathways
To identify underlying biological themes and pathways 
of the correlating proteins, a GO enrichment analysis 
using the Reactome pathway database, calculated with 
all identified SF-proteins as background was performed 
[31]. The list of synovial fluid proteins with a positive 







Fig. 2 Proteomic analysis. Gene ontology for the 266 quantified proteins visualized with the STRAP software; a Biological processes b Cellular 
component. c, d PCA analysis of identified proteins. d Grouping of technical repeats (encircled) are for the majority located together. RA patients 
are marked red and SpA patients blue. Principle component 2 mainly separates the RA and SpA patients. d Analysis of proteins that contribute to 
1st and 2nd components of PCA. Principal component 1 separates samples based on haptoglobin (HP), Fibrinogen beta chain (FGB) and several 
immunoglobulins (IG) proteins. Principal component 2 separates samples based on inflammatory proteins as Myeloperoxidase (MPO), S100-A12 
protein (S100A12), Lysozyme C (LYZ), Neutrophil gelatinase-associated lipocalin (LCN2) and Cathepsin G (GTSG). E) Comparison of RA and SpA 
protein abundances. Gene names are given for a subset of proteins passing p-value < 0.05 as determined by t-test. □: more abundant in RA, 
○: more abundant SpA, +: not significantly changed. f Student-T test of cfDNA concentrations in SF from RA and SpA patients. No significant 
difference was observed (p-value < 0.05)
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(FDR < 0.05) in five biological pathways (Table  3). 
Thirty-nine of the proteins were tagged as “Immune 
System” (R-HSA-168256), 31 as “Innate Immune 
System” (R-HSA-168249) and 26 of the 68 proteins 
(38%) were categorized as “Neutrophil degranulation” 
(R-HAS-6798695). The Glycolysis (R-HAS-70171) 
pathway was also significant enriched, in agreement 
with the anaerobic metabolism of neutrophils and lib-
eration of the cytoplasmic enzymes upon cell disrup-
tion [32].
NETs are formed in the process of NETosis where 
neutrophils ejects DNA with histones, in addition to 
cytoplasmic and secretory granules to form a web-like 
structure [33, 34]. Of the 11 most correlated proteins to 
cfDNA, 9 were known NETs proteins (Table  2, labelled 
“+”). Therefore, the presence of cfDNA correlates with 
proteins predominantly found in neutrophil granulocytes 
in both RA and SpA SF, and in  vivo liberation of DNA 
prior to sample collection is therefore likely and not a 
sampling artefact.
Twenty-nine proteins known to be associated with 
NETs formation have been identified by MS [34, 35]. Of 
these 29 proteins, 21 were identified in the SF. To visual-
ize the cfDNA correlation to NETs proteins a hierarchi-
cal clustering with the 21 proteins and SF cfDNA was 
performed (Fig.  3). The analysis showed that high con-
centration of cfDNA was correlated to presence of NETs 
proteins. NETs formation is enhanced by Resistin, that 
can be produced by synoviocytes in joints of RA patients 
[36, 37]. The receptor for Resistin is the Adenylyl cyclase-
associated protein 1 (CAP1) [36]. Accordingly, CAP1 was 
found to be more abundant in the RA group (Table 1) and 
correlated significantly and positively with cfDNA (R = 
0.5698, p-value = 1.53*10−4) (Table 2). The findings indi-
cate that NETs formation is more abundant in RA-joints 
compared to SpA, again pointing to the involvement of 
NETs in RA which recently has been demonstrated to 
sustain inflammation in other inflammatory diseases.
Correlation of plasma CRP to SF proteins
A common inflammatory marker used in SpA and RA 
is plasma-CRP, which has a half-life of 19 h [38]. There-
fore, in addition to cfDNA, the measured plasma-
CRP was correlated to protein abundances in SF, with 
the aim to identify inflammation-associated proteins. 
Forty-one proteins were found to correlate significantly 
with plasma-CRP (p-value < 0.05), 22 of which corre-
lated positively and 19 negatively. Reassuringly, SF-CRP 
correlated positively with plasma-CRP (R = 0.7148, 
p-value = 6.12*10−10), verifying the validity of the MS-
based proteomics data (Table 4). The other proteins cor-
relating positively to plasma-CRP were also acute phase 
reactants, e.g. alpha-1-antichymotrypsin, serum amyloid 
A-1 protein, and, further, other protein groups influenced 
by plasma-CRP such as complement system proteins 
(Table 4). Proteins correlating negatively included known 
“Negative” acute-phase proteins such as albumin, trans-
ferrin, transthyretin and retinol-binding protein 4 [39, 
40].
Correlation of SF proteins to plasma‑CRP and SF cfDNA
The two inflammatory markers, plasma-CRP and 
SF cfDNA correlated, but not strongly (R = 0.4765, 
p-value = 2.01*10−4). However, the proteins correlat-
ing positively or negatively to each of the two markers 
were considerably different, and of the 109 statistically 
significantly correlating proteins, only 12 (11%) were 
Table 1 Proteins with  a  significant abundance difference 
(p-value < 0.05, log2 (fold change) > ± 0.5) between  RA 
and SpA synovial fluid
a Proteins specific for neutrophile grunolocytes and monocytes
b Enzymes involved in glycolysis




281 0.010 Annexin A3
270 0.050 Annexin A1
267 0.006 Phosphoglycerate kinase 1
267 0.041 Alpha-actinin-1
263 0.047 Myeloid cell nuclear differentiation  antigena
247 0.022 Cathepsin  Ga
236 0.011 Tubulin alpha-1A chain
234 0.017 Glucose-6-phosphate  isomeraseb
232 0.035 Ras-related C3 botulinum toxin substrate 2
224 0.039 Heat shock-related 70 kDa protein 2
217 0.007 Triosephosphate  isomeraseb
213 0.030 Moesin
209 0.031 Pyruvate  kinaseb
208 0.036 Adenylyl cyclase-associated protein  1a
202 0.040 Glyceraldehyde-3-phosphate  dehydrogenaseb
189 0.024 14-3-3 protein zeta/delta
186 0.030 Beta-2-microglobulin
179 0.026 Profilin-1
171 0.015 Phosphoglycerate mutase  1b
164 0.041 Plastin-2
160 0.037 Transgelin-2
151 0.010 Retinol-binding protein 4
145 0.026 Complement factor D
144 0.044 Transketolase
62 0.043 Serum amyloid P-component
43 0.019 Ig alpha-1 chain C region
40 0.027 Ig lambda-6 chain C region
22 0.038 Haptoglobin
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Table 2 Correlation Analysis: Synovial fluid proteins identified by  mass spectrometry across  all RA and  SpA samples 
correlating significantly (p-value < 0.05) to synovial fluid cfDNA
UPID Protein name Gene name R p‑value NETs
P62805 Histone H4 HIST1H4A 0.9170 1.52E−06 +
P14780 Matrix metalloproteinase-9 MMP9 0.8141 4.02E−06 +
P80188 Neutrophil gelatinase-associated lipocalin LCN2 0.7925 3.88E−08 +
P07900 Heat shock protein HSP 90-alpha HSP90AA1 0.7314 4.40E−06
P37837 Transaldolase TALDO1 0.7292 7.12E−03
P02788 Lactotransferrin LTF 0.7158 5.62E−10 +
P20160 Azurocidin AZU1 0.7114 4.61E−05 +
Q99880 Histone H2B type 1-L HIST1H2BL 0.7008 1.61E−05 +
P12814 Alpha-actinin-1 ACTN1 0.6964 3.86E−05 +
P61626 Lysozyme C LYZ 0.6946 1.57E−08 +
P24158 Myeloblastin PRTN3 0.6803 4.89E−05 +
P15153 Ras-related C3 botulinum toxin substrate 2 RAC2 0.6803 1.31E−04
P52566 Rho GDP-dissociation inhibitor 2 ARHGDIB 0.6694 1.25E−03
P08246 Neutrophil elastase ELANE 0.6660 1.35E−03 +
P05164 Myeloperoxidase MPO 0.6584 4.89E−07 +
P52209 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.6529 4.04E−04
P0DMV9 Heat shock 70 kDa protein 1B HSPA1B 0.6524 1.35E−03
P63261 Actin, cytoplasmic 2 ACTG1 0.6419 1.28E−07
P00558 Phosphoglycerate kinase 1 PGK1 0.6270 3.28E−05
Q99878 Histone H2A type 1-J HIST1H2AJ 0.6265 1.05E−03 +
P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 0.6096 3.33E−06
P06744 Glucose-6-phosphate isomerase GPI 0.6007 3.99E−03
P12429 Annexin A3 ANXA3 0.5955 2.14E−03
P08311 Cathepsin G CTSG 0.5944 1.66E−04 +
P06733 Alpha-enolase ENO1 0.5942 1.38E−06 +
P14618 Pyruvate kinase PKM PKM 0.5898 2.15E−06
P06702 Protein S100-A9 S100A9 0.5857 2.12E−06 +
P07737 Profilin-1 PFN1 0.5778 5.90E−06
P08670 Vimentin VIM 0.5745 1.58E−05
P60174 Triosephosphate isomerase TPI1 0.5720 4.09E−04
P13796 Plastin-2 LCP1 0.5704 5.45E−06 +
Q01518 Adenylyl cyclase-associated protein 1 CAP1 0.5698 1.53E−04
P09211 Glutathione S-transferase P GSTP1 0.5578 1.67E−03
P00338 l-Lactate dehydrogenase A chain LDHA 0.5531 4.14E−03
P04083 Annexin A1 ANXA1 0.5486 1.40E−04
P01033 Metalloproteinase inhibitor 1 TIMP1 0.5463 3.21E−04
P26038 Moesin MSN 0.5314 4.19E−04
P62937 Peptidyl-prolyl cis-trans isomerase A PPIA 0.5142 1.85E−04
P30740 Leukocyte elastase inhibitor SERPINB1 0.5103 4.34E−02
P18669 Phosphoglycerate mutase 1 PGAM1 0.5080 3.13E−04
Q71U36 Tubulin alpha-1A chain TUBA1A 0.4917 1.07E−02
P22894 Neutrophil collagenase MMP8 0.4728 4.74E−03
P80511 Protein S100-A12 S100A12 0.4689 5.16E−03
P63104 14-3-3 protein zeta/delta YWHAZ 0.4675 2.70E−03
P29401 Transketolase TKT 0.4575 1.58E−03
P09960 Leukotriene A-4 hydrolase LTA4H 0.4572 3.91E−03
P23528 Cofilin-1 CFL1 0.4462 1.89E−03
P68133 Actin, alpha skeletal muscle ACTA1 0.4370 2.01E−02
P08133 Annexin A6 ANXA6 0.4199 7.79E−03
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common (Tables  2, 4). Hierarchical clustering with 
positive correlated proteins to both cfDNA (Fig.  3) 
and positive as well as negative correlated proteins to 
plasma CRP, showed a distinct clustering (Fig.  3) with 
a group of 11, predominantly RA patients with NETs 
markers (Fig.  3, left). Three of these patients were in 
biological treatment, showing that the treatment was 
not responsible for the generation of cfDNA. A group 
of 10, predominantly SpA patients, correlated with 
acute phase reactants without NETs proteins (Fig.  3, 
right), demonstrating the involvement of NETs in RA 
and the likely subgrouping of the SpA patients. On 
average a stronger correlating with cfDNA to granulo-
cyte proteins (mean absolute difference 0.13, p-value 
1.15*10−6) were seen than to plasma CRP.
Discussion
The findings presented in the present study is, to our 
knowledge, the first unbiased proteomic approach of 
examining and comparing RA and SpA SF protein com-
position. The findings were further correlated with 
plasma CRP levels and SF cfDNA for discriminating 
factors. Among the RA patients, proteins from neutro-
phils were more dominant in SF. Haptoglobin was the 
only protein found reduced in SF from RA compared 
with SpA patients, in accordance with higher levels of 
the scavenging receptor for haptoglobin–haemoglobin 
CD163 in RA patients [41]. Proteins from neutrophils 
and glycolytic enzymes correlated strongly to cfDNA 
in SF predominantly from RA patients. CRP and other 
acute phase reactants were seen in both RA and SpA 
patients, but high amounts of acute phase reactants were 
also detected in SpA patients without neutrophil granu-
locyte markers.
NETs is formed by neutrophils undergoing NETosis, 
where DNA is expelled from the cells within the tis-
sue lining and in biofluids to form web-like structures 
together with histones, S100-proteins, and proteins 
stored in secretory granules (Fig.  4) [34]. NETs mark-
ers, as circulating cfDNA, can be used to monitor treat-
ment efficiency of biological DMARD in RA patients 
[29].
Correlation of SF cfDNA to known NETs proteins in SF 
was found, indicating that the origin of cfDNA was from 
Table 2 (continued)
UPID Protein name Gene name R p‑value NETs
P02679 Fibrinogen gamma chain FGG 0.4183 1.34E−03
P36222 Chitinase-3-like protein 1 CHI3L1 0.4106 7.67E−03
P12111 Collagen alpha-3(VI) chain COL6A3 0.3898 3.26E−03
P07195 l-Lactate dehydrogenase B chain LDHB 0.3686 3.19E−02
P04075 Fructose-bisphosphate aldolase A ALDOA 0.3684 2.94E−02
P02741 C-reactive protein CRP 0.3470 8.78E−03
P04003 C4b-binding protein alpha chain C4BPA 0.3119 2.17E−02
P02763 Alpha-1-acid glycoprotein 1 ORM1 0.3061 2.18E−02
P02750 Leucine-rich alpha-2-glycoprotein LRG1 0.3046 2.24E−02
P04040 Catalase CAT 0.2955 2.70E−02
P07225 Vitamin K-dependent protein S PROS1 0.2941 2.78E−02
P08603 Complement factor H CFH 0.2883 3.12E−02
P0DJI8 Serum amyloid A-1 protein SAA1 0.2866 3.56E−02
P60709 Actin, cytoplasmic 1 ACTB 0.2793 4.09E−02
P49747 Cartilage oligomeric matrix protein COMP − 0.2706 4.37E−02
P02751 Fibronectin FN1 − 0.2939 2.79E−02
Q13790 Apolipoprotein F APOF − 0.4627 3.02E−03
Q96RL7 Vacuolar protein sorting-associated protein 13A VPS13A − 0.5619 1.23E−02
Q66K66 Transmembrane protein 198 TMEM198 − 0.5646 2.27E−02
Table 3 Statistical significant enriched Reactome 
biological pathways for synovial fluid proteins associated 
with the synovial fluid cfDNA concentration
Reactome ID Name #Proteins FDR
R-HSA-70171 Glycolysis 8 1.15e−02
R-HSA-6798695 Neutrophil degranulation 26 1.15e−02
R-HSA-71387 Metabolism of carbohydrates 11 3.36e−02
R-HSA-70263 Gluconeogenesis 7 4.85e−02
R-HSA-168256 Immune system 39 4.85e−02
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neutrophils and thereby that NETosis likely had occurred 
in the joints in vivo. Due to the presence of both the cyto-
plasmic S100-proteins and the nuclear histone proteins, 
degranulation of neutrophils without NETosis is unlikely. 
The DNA-binding protein, Histone H4, is the most corre-
lated protein with cfDNA. Furthermore, MMP9, NGAL 
(Neutrophil gelatinase-associated lipocalin) and other 
NETs proteins were also strongly correlated to the pres-
ence of cfDNA in the samples (Table  2), indicating that 
the cfDNA originated from NETosis process. Cytoplas-
mic proteins as Glucose-6-phosphate isomerase and 
Glyceraldehyde-3-phosphate dehydrogenase correlated 
also to cfDNA indicating cell rupture (Fig. 4).
Neutrophils contain many proteases with tissue 
destructive effects. In the SF with high cfDNA, MMP9, 
MMP8, neutrophil elastase, Myeloblastin and Cathep-
sin G, that can contribute to destruction, were found 
(Table  2). MMP9 forms a high molecular weight com-
plex with NGAL, that protects MMP9 from degradation 
and thereby prolongs its proteolytic activity and tissue 
destruction [42]. NGAL is upregulated in human neu-
trophils by granulocyte-macrophage colony-stimulating 
(GM-CSF), and in SF of RA compared to OA patients, 
higher concentrations of NGAL was measured [43]. This 
is in agreement with reports of higher plasma MMP9 in 
RA patients compared with OA, and that a higher enzy-
matic activity was found in SF of RA patients [44, 45]. 
Furthermore, neutrophils from RA patients compared 
to healthy controls have a tendency to undergo NETosis 
easier when treated with PMA [18]. MMP9 could also be 
produced by synoviocytes in SF from RA patients, but its 
high correlation to cfDNA shows that the MMP9 most 
likely originated from neutrophils [46].
Metalloproteinase inhibitor 1 and Leukocyte elastase 
inhibitor both correlated to cfDNA, but the cell type pro-
ducing these inhibitors are unclear (Fig. 4). Metallopro-
teinase inhibitor 1 can form a complex with MMP9 and 
NGAL. Therefore, the in vivo MMP9 activity is difficult 
Fig. 3 Hierarchical clustering of cfDNA and plasm CRP correlated proteins. For the clustering all proteins correlating positive R > 0.5 or negativ R 
< − 0.5 to plasma CRP or cfDNA were selected (Tables 2, 4). Values of plasma CRP (log2) and cfDNA (log2) were included in the clustering (labelled 
green). The diagnosis is marked over the clustering. NGAL is the abbreviation for Neutrophil gelatinase-associated lipocalin
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Table 4 SF proteins identified by proteomics with statistically significant correlation (p-value < 0.05) to plasma CRP
Proteins marked with * are also positive correlated to SF cfDNA
UPID Protein name Gene name R p value
P0DJI8 Serum amyloid A-1 protein* SAA1 0.7254 5.47E−10
P02741 C-reactive protein* CRP 0.7148 6.12E−10
P02750 Leucine-rich alpha-2-glycoprotein* LRG1 0.5769 3.26E−06
P02679 Fibrinogen gamma chain* FGG 0.5399 1.75E−05
Q7Z4H8 KDEL motif-containing protein 2 KDELC2 0.4856 4.82E−02
P18428 Lipopolysaccharide-binding protein LBP 0.4765 2.05E−04
P07225 Vitamin K-dependent protein S* PROS1 0.4328 8.64E−04
Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 ITIH3 0.4321 9.85E−04
P00751 Complement factor B CFB 0.4182 1.34E−03
P02671 Fibrinogen alpha chain FGA 0.3954 2.56E−03
P06702 Protein S100-A9* S100A9 0.3913 2.86E−03
P02748 Complement component C9 C9 0.3893 3.02E−03
P01011 Alpha-1-antichymotrypsin SERPINA3 0.3868 3.23E−03
P01009 Alpha-1-antitrypsin SERPINA1 0.3865 3.26E−03
P68133 Actin, alpha skeletal muscle* ACTA1 0.3791 4.66E−02
P02743 Serum amyloid P-component APCS 0.3657 6.03E−03
P08603 Complement factor H* CFH 0.3298 1.30E−02
P36222 Chitinase-3-like protein 1* CHI3L1 0.3170 4.34E−02
P02788 Lactotransferrin* LTF 0.3042 2.26E−02
P05156 Complement factor I CFI 0.2866 3.23E−02
P04003 C4b-binding protein alpha chain* C4BPA 0.2727 4.60E−02
Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 0.2683 4.56E−02
P27169 Serum paraoxonase/arylesterase 1 PON1 − 0.2719 4.27E−02
P02753 Retinol-binding protein 4 RBP4 − 0.2900 3.02E−02
P05452 Tetranectin CLEC3B − 0.2923 2.88E−02
P02656 Apolipoprotein C-III APOC3 − 0.2934 2.82E−02
Q92954 Proteoglycan 4 PRG4 − 0.2970 2.62E−02
P01871 Ig mu chain C region IGHM − 0.2997 2.48E−02
P19823 Inter-alpha-trypsin inhibitor heavy chain H2 ITIH2 − 0.3006 2.44E−02
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 ITIH1 − 0.3293 1.32E−02
P02751 Fibronectin* FN1 − 0.3301 1.30E−02
P22352 Glutathione peroxidase 3 GPX3 − 0.3325 2.74E−02
P02647 Apolipoprotein A-I APOA1 − 0.3343 1.18E−02
P43652 Afamin AFM − 0.3650 5.67E−03
P02787 Transferrin TF − 0.3669 5.41E−03
P05154 Plasma serine protease inhibitor SERPINA5 − 0.3706 9.51E−03
P06396 Gelsolin GSN − 0.3730 4.63E−03
P02768 Albumin ALB − 0.4892 1.30E−04
Q96PD5 N-Acetylmuramoyl-L-alanine amidase PGLYRP2 − 0.5021 8.06E−05
P02766 Transthyretin TTR − 0.5277 2.93E−05
P29622 Kallistatin SERPINA4 − 0.5492 1.17E−05
Fig. 4 Localization of neutrophil proteins that correlate to cfDNA detected in SF. a Schematic drawing of a neutrophil and localisation of proteins 
correlating to cfDNA. Nucleus (blue) shows DNA and chromatin. Cytoplasmic granules are shown in pink. Annexin 1 is present in the granular 
membranes but translocated to the cytoplasmic membrane upon degranulation/NETs formation. Cytoplasm (light pink). b During NETosis proteins 
from all compartments can be released. In inflamed RA joint—both granular, cytoplasmic, nuclear proteins, Annexin 1 and cfDNA were detected 
in SF. Annexin 1 is an inhibitor of migration of neutrophil to inflammation. Metalloproteinase inhibitor 1 and Leukocyte elastase inhibitor were 
correlated to cfDNA. The origin of these inhibitors is unknown
(See figure on next page.)
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to determine. Ahrens et al. [45] have shown active MMP9 
gelatinase activity in SF from RA patients by use of gel 
zymography, and thus, MMP9 was separated from Met-
alloproteinase inhibitor 1. Annexin 1, released by neu-
trophils, is an inhibitor of migration of neutrophils from 
the blood to the inflamed site, and even though Annexin 
1 was present in the SF with cfDNA, it was unable to pre-
vent disease progression (Fig 4).
Katano et  al. [43] proposed GM-CSF as a target for 
treatment of RA and this is now supported by human tri-
als. Patients with high SF cfDNA and NGAL could there-
fore be a distinct clinical endotype that may benefit from 
such a treatment [47]. Sato et al. [37] proposed that Resis-
tin produced by synovial tissue could be important for 
the pathogenesis of RA. The receptor for Resistin, CAP1, 
was present in SF and correlated to cfDNA. CAP1 is a 
cytoplasmic protein, but is translocated to the cell mem-
brane when Resistin is present [48]. Resistin enhances 
NETosis [36], but whether CAP1 in SF can function as a 
receptor antagonist in its free form is presently unknown.
Plasma CRP is a central marker used in combination 
with 28-joint Disease Activity Score (DAS28CRP) and 
Ankylosing Spondylitis Disease Activity Score (ASDAS) 
to determine disease progression and treatment success, 
that correlates to disease progression [49]. When plasma 
CRP was correlated to SF proteomic data, other known 
positively and negatively regulated acute phase reactants 
were found (Tables  3 and 4, Fig.  3). Proteins correlated 
to plasma CRP and cfDNA, respectively, had only 12% 
proteins in common. Leucine-rich alpha-2-glycoprotein 
(LRG1) is correlated to both CRP and cfDNA. It is an 
acute phase protein induced primarily by IL-6 in the liver 
[50, 51], but is also a neutrophil secondary granule pro-
tein released together with lactoferrin, and thus its corre-
lation to both CRP and cfDNA is explainable [52]. LRG1 
inhibits the anti-proliferative effect of transforming 
growth factor ß1 (TGFß1) on myeloid cells [51]. TGFß1 
regulates the anti-inflammatory process in the synovial 
membrane in RA patients, and is important for the self-
regulation that can result in remission periods [53]. In RA 
patients treated with anti-interleukin-6 receptor antibody 
(RoActemra) LRG1 was a better marker for remission 
than CRP, matrix metalloproteinase 3 level and eryth-
rocyte sedimentation rate [54]. As shown in the present 
study, this can be due to LRG1 being a maker for both 
acute phase reactants and for neutrophil degranula-
tion/NETosis. As shown in Fig. 3, a group of manly SpA 
patients had high CRP and acute phase reactants without 
granulocyte markers, confirming the central role of neu-
trophil granulocytes in the pathogenesis of RA.
The differences between RA and SpA identified here 
are in line with results from randomized clinical tri-
als with already approved drugs. Thus, T-cell targeted 
therapies such as inhibitors of IL-17 has shown efficacy 
in SpA but not in RA. In contrast, therapies targeting 
myeloid derived cytokines such as inhibitors of IL-1 and 
IL-6 are effective in RA but not in SpA [55]. Our find-
ings also support that RA is a very heterogenous dis-
ease as proposed by others [56]. Thus, a subgroup of RA 
patients with high neutrophil activation was found. High 
degree of neutrophil priming and NETosis is also present 
in other diseases such as systemic lupus erythematosus 
and granulomatosis with polyangiitis [33, 57]. Some of 
the drugs used for treatment of these diseases such as the 
C5a receptor inhibitor  Avacopan® could, therefore, also 
be effective in RA patients with high neutrophil activa-
tion. In this way, the study could help guide future drug 
development to treat immune mediated inflammatory 
arthritis.
Conclusions
The proteomics of SF from SpA and RA patients showed 
a marked difference in the amounts of proteins from the 
innate immune system, primarily originating from neu-
trophil granulocytes. The presence of these proteins was 
more pronounced in the RA patient group. These pro-
teins were also correlated to SF cfDNA indicating NETo-
sis. Neutrophils produce IL-6 that induces acute phase 
reactants, but surprisingly, little correlation between 
NETs proteins/cfDNA and acute phase reactants/CRP 
was seen, indicating that two different inflammatory 
mechanisms are used for increase in CRP and cfDNA. 
This is in agreement with the recent finding that mature 
neutrophils are unresponsive to IL-6 due to the absence 
of gp130 in the IL-6 receptor complex [58]. Some of the 
patients with high cfDNA were in treatment with anti-
interleukin-6 receptor  (RoActemra®) or TNF-α antago-
nists. This may have influenced the amounts of acute 
phase reactants. However, in a patient material as pre-
sented in this study, SF cfDNA is an indicator of intraar-
ticular NETosis. Therefore, SF cfDNA measurement may 
be used as an indicator of severe arthritis, and our find-
ings demonstrate the involvement of NETs in RA but less 
in SpA pathogenesis.
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